A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Inclusion Criteria: * Adult patients, \>/=18 years of age * Chronic hepatitis C infection for at least 6 months duration * Hepatitis C genotype 1a or 1b * Patients must have discontinued prior hepatitis C treatment at least 12 weeks prior to enrollment in this study * Patient showed a previous null response to therapy as defined by \< 2 log10 IU/mL decrease in viral titer after at least 12 weeks of treatment with PEG-IFN/RBV Exclusion Criteria: * Hepatitis C infection with a genotype other than genotype 1a or 1b * Body mass index \<18 or \>/=36 * Hepatitis A, hepatitis B, or HIV infection * Herbal remedies \</=1 month prior to the first dose of study drug